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Marked improvement of cytotoxic effects
induced by docetaxel on highly metastatic
and androgen-independent prostate cancer
cells by downregulating macrophage
inhibitory cytokine-1
M Mimeault*,1, S L Johansson2 and S K Batra*,1,2
1

Department of Biochemistry and Molecular Biology, College of Medicine, Eppley Cancer Center, University of Nebraska Medical
Center, Omaha, NE 68198-5870, USA and 2Department of Pathology and Microbiology, College of Medicine, Eppley Cancer Center,
University of Nebraska Medical Center, Omaha, NE 68198-5870, USA
Background: Overexpression of macrophage inhibitory cytokine-1 (MIC-1) frequently occurs during the progression of prostate
cancer (PC) to androgen-independent (AI) and metastatic disease states and is associated with a poor outcome of patients.
Methods: The gain- and loss-of-function analyses of MIC-1 were performed to establish its implications for aggressive and
chemoresistant phenotypes of metastatic and AI PC cells and the benefit of its downregulation for reversing docetaxel resistance.
Results: The results have indicated that an enhanced level of secreted MIC-1 protein in PC3 cells is associated with their
acquisition of epithelial–mesenchymal transition features and higher invasive capacity and docetaxel resistance. Importantly, the
downregulation of MIC-1 in LNCaP-LN3 and PC3M-LN4 cells significantly decreased their invasive capacity and promoted the
antiproliferative, anti-invasive and mitochrondrial- and caspase-dependent apoptotic effects induced by docetaxel. The
downregulation of MIC-1 in PC3M-LN4 cells was also effective in promoting the cytotoxic effects induced by docetaxel on the side
population (SP) endowed with stem cell-like properties and the non-SP cell fraction from PC3M-LN4 cells.
Conclusion: These data suggest that the downregulation of MIC-1 may constitute a potential therapeutic strategy for improving
the efficacy of current docetaxel-based chemotherapies, eradicating the total mass of PC cells and thereby preventing disease
relapse and the death of PC patients.

Human macrophage inhibitory cytokine-1 (MIC-1), also known as
growth and differentiation factor-15 (GDF-15), is a divergent
member of the transforming growth factor-b (TGF-b)/bone
morphogenic protein superfamily (Mimeault and Batra, 2010a).
The MIC-1 plays key physiological roles during the prenatal
development and regulation of growth and differentiation, cartilage
and bone formation, cellular responses to stress and inflammation
and tissue repair after acute injuries in postnatal and adult life

(Mimeault and Batra, 2010a). The MIC-1 protein has attracted
much attention following the demonstration that it is overexpressed during the progression of numerous aggressive and
recurrent cancers, including prostate cancer (PC), and represents a
determinant factor associated with tumour growth, metastases,
treatment resistance and poor outcome of cancer patients (Lee
et al, 2003; Liu et al, 2003; Nakamura et al, 2003; Welsh et al, 2003;
Cheung et al, 2004; Bauskin et al, 2005; Wollmann et al, 2005;
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Brown et al, 2006; Chen et al, 2007; Huang et al, 2007; Kim et al,
2008; Boyle et al, 2009; Zhang et al, 2009; Huh et al, 2010;
Mimeault and Batra, 2010a; Senapati et al, 2010). More recently,
the serum level of MIC-1 has also been proposed as a new potential
marker of all-cause mortality and/or predictor of disease progression, including for various cancers, cardiovascular diseases, chronic
renal failure and pulmonary emboli (Wiklund et al, 2010).
Although the MIC-1 receptors have not been precisely
identified, it has been reported that the secreted MIC-1 protein
can induce its biological effects through the activation of type I and
type II membrane serine/threonine kinase receptors for TGF-b
family members (Tan et al, 2000; Xu et al, 2006; Johnen et al, 2007;
Soto-Cerrato et al, 2007; Ago et al, 2010; Mimeault and Batra,
2010a). In fact, in analogy with TGF-b family ligands, MIC-1 can
display dual functions, by inducing growth arrest and differentiation in normal epithelial cells while promoting proliferation,
invasion and metastases of PC cells (Lee et al, 2003; Wollmann
et al, 2005; Chen et al, 2007; Noorali et al, 2007; Kim et al, 2008;
Boyle et al, 2009; Huh et al, 2010; Mimeault and Batra, 2010a;
Senapati et al, 2010; Mimeault et al, 2012). This is likely because of
the alterations in signal transduction mechanisms mediating the
anticarcinogenic effects of MIC-1 in cancer cells and its
immunosuppressive effects (Lee et al, 2003; Wollmann et al,
2005; Chen et al, 2007; Noorali et al, 2007; Kim et al, 2008; Boyle
et al, 2009; Huh et al, 2010; Mimeault and Batra, 2010a, b; Senapati
et al, 2010). Moreover, it has been reported that the oncogenic
effects induced by the secreted MIC-1 protein may be mediated in
part through the activation of epidermal growth factor receptor
(EGFR) family members, mitogen-activated protein kinases
(MAPKs), phosphatidylinositol 30 -kinase/Akt, focal adhesion
kinase (FAK) and/or urokinase-type plasminogen activator system
in a cancer cell type- and context-dependent manner as well as via
the induction of the angiogenic process (Lee et al, 2003; Wollmann
et al, 2005; Chen et al, 2007; Kim et al, 2008; Boyle et al, 2009; Huh
et al, 2010; Mimeault and Batra, 2010a; Senapati et al, 2010;
Mimeault et al, 2012).
A progressive increase of MIC-1 levels in PC cells and serum
samples has also been observed during PC progression to
androgen-independent (AI) and metastatic disease states and
associated with treatment resistance and a poor prognosis for PC
patients (Karan et al, 2002; Welsh et al, 2003; Zheng et al, 2003;
Cheung et al, 2004; Bauskin et al, 2005; Brown et al, 2006; Chen
et al, 2007; Huang et al, 2007; Patrikainen et al, 2007; Selander
et al, 2007; Wakchoure et al, 2009; Zhao et al, 2009; Mimeault and
Batra, 2010a; Senapati et al, 2010; Mimeault et al, 2012). The
results from our recent work, and prior studies, have also indicated
a functional role of MIC-1 for the sustained growth, reduced
intercellular adhesion and enhanced invasive and metastatic
properties of PC cells (Liu et al, 2003; Chen et al, 2007; Huang
et al, 2007; Patrikainen et al, 2007; Zhao et al, 2009; Mimeault and
Batra, 2010a; Senapati et al, 2010; Mimeault et al, 2012). In
addition, the overexpression of MIC-1 in PC cells has also been
linked with the formation of bone metastases and osteoblastic/lytic
lesions, which are associated with severe pain in PC patients as well
as tumour-induced anorexia and weight loss in late-stage disease
(Chen et al, 2007; Johnen et al, 2007; Wakchoure et al, 2009; Zhao
et al, 2009; Senapati et al, 2010).
Additional studies are still necessary to more precisely define the
molecular mechanisms of MIC-1 functions for the acquisition of a
more malignant behaviour and chemoresistant phenotypes by PC
cells during disease progression to metastatic castration-resistant
prostate cancers (CRPCs) and the therapeutic interest of its
downregulation for reversing chemoresistance. Therefore, gainand loss-of-function studies were undertaken to establish the MIC-1
implication in the resistance of metastatic and AI PC cells to the
cytotoxic effects induced by current chemotherapeutic drug,
docetaxel, which is used for treating patients with locally advanced
1080
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and metastatic CRPCs. Overall, the results have indicated therapeutic benefits of downregulating the MIC-1 protein to improve the
anticarcinogenic effects induced by docetaxel on metastatic and AI
PC cells, including CD133 þ and CD133- PC cell fractions, and
eradicate the total mass of PC cells.
MATERIALS AND METHODS

Materials and cell cultures. The human metastatic and AI PC3
cell line was originally purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA) and authenticated by
short tandem repeat analysis. PC3 cells were used at o20 passages
after purchase from ATCC. The well-characterised and highly
metastatic and AI LNCaP-LN3 and PC3M-LN4 cell variants of
parental LNCaP and PC3 cells, respectively, were established and
kindly provided by Dr Isaak J Fidler (University of Texas MD
Anderson Cancer Center, Houston, TX, USA) (Pettaway et al,
1996). A pooled population of stable clones of MIC-1-transfected
PC3 cells overexpressing functional MIC-1 protein (PC3-MIC-1)
and empty-vector (pMSCV.puro)-transfected PC3 cell lines
(PC3-Vec) was established in our laboratory as previously
described (Senapati et al, 2010). The LNCaP-LN3-siMIC-1 and
PC3M-LN4-siMIC-1 cells in which MIC-1 was downregulated by
stealth RNAi-mediated approach as well as LNCaP-LN3-Con
and PC3M-LN4-Con cells transfected with control siRNA oligos
and expressing high endogenous level of MIC-1 used as a control
were prepared as previously described (Senapati et al, 2010). All PC
cells and their derivative cell lines were maintained as
recommended by ATCC guidelines in regular phenol red-free
RPMI-1640 culture medium (Gibco, Grand Island, NY, USA)
supplemented with 10% fetal bovine serum (FBS), 1% glutamine
and 1% penicillin–streptomycin in a 37 1C incubator supplied with
5% CO2 and routinely tested for morphological features and
mycoplasms (Roche Diagnostics, Indianapolis, IN, USA).
All culture materials were purchased from Life Technologies
(Carlsbad, CA, USA) and human recombinant MIC-1 protein
(rhMIC-1) was obtained from R&D Systems (Minneapolis, MN,
USA). In addition, SB431542, docetaxel, 30 ,30 -dihexyloxacarbocyanine iodide (DiOC6(3)), (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and EGF were purchased from
Sigma-Aldrich (St Louis, MO, USA) and N-benzyloxycarbonylVal-Ala-Asp-fluoromethylketone (Z-VAD-FMK) from Calbiochem Corp. (San Diego, CA, USA). The mouse monoclonal antivimentin (V6630) and anti-b-actin (clone AC-15) antibodies were
purchased from Sigma-Aldrich and mouse anti-E-cadherin and
anti-N-cadherin were obtained from BD Biosciences (Franklin
Lakes, NJ, USA). The rabbit polyclonal anti-CD133 antibody (H284) and anti-ABCG2 antibody (B-25), mouse monoclonal antiCD44 (HCAM, F-4) antibody and anti-cytochrome c (6H2)
antibody were provided by Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA, USA). The rabbit polyclonal anti-MIC-1 antibody was
generated in our laboratory as previously described (Chen et al,
2007). Moreover, rabbit polyclonal antibody directed against the
cleaved fragment of caspase-9 or caspase-3 was purchased from
Cell Signaling Technology (Danvers, MA, USA), and rabbit
polyclonal antibody recognising the cleaved human poly (ADPribose) polymerase (PARP; 197–214) fragment was obtained from
Calbiochem, Inc. (San Diego, CA, USA). The phycoerythrinconjugated monoclonal anti-CD133/2 antibody (293C3) was
purchased from Miltenyi Biotec Inc. (Auburn, CA, USA) and
employed according to the manufacturer’s instructions.
Immunohistochemical analyses. Immunohistochemical studies
on the expression of the MIC-1 protein in nonmalignant and
malignant prostate tissues were done as previously described by a
peroxidase method using the VECTASTAIN avidin-biotin
www.bjcancer.com | DOI:10.1038/bjc.2012.484

MIC-1 functions in the chemoresistance of PC cells

complex (ABC) kit as indicated in manufacturer’s instructions
from Vector Laboratories (Burlingame, CA, USA) (Mimeault et al,
2007a, b, 2010a, b, 2012). Immunostaining was carried out on
AccuMax array tissue sections (Petagen, Inc., Shinchon-dong,
Seoul, Korea) containing 8 normal prostatic tissue specimens of
biopsy as well as AccuMax array containing 32 pairs of tissue
sections from patients with primary prostatic adenocarcinoma
(Gleason scores 7–9) with their corresponding adjacent benign
tissues from the same patients. A reddish brown colour precipitate
observed on tissue sections is indicative of a positive immunoreactivity with the tested primary antibody. For each tissue section,
the intensity of immunoreactivity for the MIC-1 protein was
semiquantitatively graded by a urological pathologist (SLJ) on a 0
to þ 3 scale (0 ¼ no staining, 1 þ ¼ week staining, 2 þ ¼ moderately strong and 3 þ ¼ strong staining). The percentage of PC
cells positive for MIC-1 staining within a given tissue core was also
scored on a 1 to 4 scale (1 ¼ 0–25% positive PC cells, 2 ¼ 26–50%
positive cells, 3 ¼ 51–75% positive cells and 4 ¼ 76–100% positive
cells). The score of the staining intensity and the percentage of
immunoreactive PC cells were then multiplied to obtain a
composite score ranging from 0 to 12. The staining intensity of
MIC-1 protein in prostate adenocarcinoma samples was scored
and compared with normal and adjacent benign prostatic tissues,
and the value was considered enhanced if the staining intensity was
higher by one or more points.
Immunoblot and immunofluorescence analyses. The samples of
PC cell lysates, conditioned medium or cytosolic fraction corresponding to 20 mg proteins were resolved by electrophoresis on an
8% or 10% SDS-agarose gel under reducing conditions as
previously described (Mimeault et al, 2006, 2007a, b, 2010b,
2012). The proteins were transferred onto an immobilon-P transfer
membrane and blocked in 5% non-fat dry milk in PBS for 2 h and
subjected to the standard immunodetection procedure. At the end
of incubation, the blot was washed in TBST (50 mM Tris-HCl, pH
7.4, 150 mM NaCl and 0.05% Tween) and incubated with
horseradish peroxidase-conjugated secondary antibody (Amersham Biosciences, Piscataway, NJ, USA) for 1 h. Antibody–antigen
complexes were visualised using enhanced chemiluminescence kit
(Amersham Biosciences).
Confocal immunofluorescence microscopy. Prostate cancer cells
were grown at a low density on sterilised cover slips for 24 h. After
washing with PBS, cells were fixed in ice-cold methanol at ÿ 20 1C
for 2 min (Mimeault et al, 2007a, b, 2010a, b, 2012). For phalloidin
staining, PC cells were fixed in 3.7% formaldehyde-PBS solution for
10 min at room temperature, washed twice with PBS and
permeabilised with 0.1% Triton X-100 in PBS for 3–5 min at room
temperature. After washing with PBS, nonspecific blocking was
carried out using 10% goat serum for 30 min. After the blocking step
and a quick wash in PBS, cells were incubated with an antibody
directed against E-cadherin, N-cadherin, vimentin, b-actin, ABCG2,
CD44, MIC-1 or EGFR/Tyr1173-pEGFR for 1 h at room temperature.
After three washes with PBS, the cells were then incubated with
fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse, FITCconjugated donkey anti-goat and/or Texas red-conjugated goat antirabbit secondary antibody (Jackson ImmunoResearch Laboratories,
Inc., West Grove, PA, USA) for 1 h. For F-actin staining, cells were
incubated with rhodamine phalloidin (R415; Molecular Probes,
Eugene, OR, USA) for 20 min at room temperature. Cells were
washed again three times with PBS, nuclei counterstained with
diamidino-2-phenylindole (DAPI) and mounted on glass slides in
anti-fade Vestashield mounting medium (Vector Laboratories). The
stained cells were observed under a confocal laser-scanning
microscope (LSM 410, Zeiss, Gottingen, Germany) and photographs
were taken digitally using LSM 510 software.
www.bjcancer.com | DOI:10.1038/bjc.2012.484
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Cell growth and flow cytofluorimetric analyses. For growth
assays, PC cells were seeded on 96-well plates at a density of
3  104 cells per well in a culture medium containing 0.5% FBS and
untreated or treated with 2–10 nM docetaxel (Mimeault et al, 2006,
2007a, b, 2010a, b, 2012). After incubation for 48 h, the rate of cell
growth was estimated by a MTT colorimetric test. For flow
cytofluorimetric analyses, all tested PC cells were grown at a
density of 5  105 cells on 25 cm2 dishes. Fluorescence-activated
cell sorting (FACS) analyses of cell populations in cell cycle phases
were performed after 48-h incubation of PC cells with 2–10 nM
docetaxel (Mimeault et al, 2005, 2006, 2007a, b, 2010a, b, 2012).
The cells were untreated or treated with 2–10 nM docetaxel in the
absence or presence of broad caspase inhibitor Z-VAD-FMK at
50 mM for 4 days. The apoptotic effect induced by docetaxel on PC
cells was estimated by FACS analyses by staining of each sample
with the propidium iodide as previously described (Mimeault et al,
2005, 2006, 2007a, b, 2010a, b, 2012).
In vitro invasion assays. Parental PC3 cells were untreated
(control) or pretreated with 1 ng ml ÿ 1 rhMIC-1 protein in the
presence or absence of 10 mM SB431542, which is a selective and
potent inhibitor of the TGF-b superfamily type I activin receptorlike kinase (ALK) receptor, including ALK4, ALK5 and ALK7, or
10 nM docetaxel for 24 h, and during cell invasion assay for an
additional 24 h. Moreover, PC3-Vect vs PC3-MIC-1 cells as well as
LNCaP-LN3-Con vs LNCaP-LN3-siMIC-1 and PC3M-LN4-Con vs
PC3M-LN4-siMIC-1 cells were untreated (control) or pretreated
with 10 nM docetaxel for 24 h, and during cell invasion assay
for an additional 24 h. For each experiment, 3  105 PC cells per
well in a total volume of 2 ml serum-free medium without
rhMIC-1 and docetaxel (control) or containing 1 ng ml ÿ 1 rhMIC1 and/or 10 nM docetaxel were loaded into the top of the BioCoat
matrigel cell invasion chamber (BD Biosciences, Bedford, MA,
USA). The bottom chamber of the well was filled with 2.0 ml of
10% serum-containing medium as a chemoattractant solution and
the cells were allowed to migrate for 24 h at 37 1C under
chemotactic drive. At the end of incubation, the invasive cells
reaching the lower chamber were stained with a Diff-Quick
stain set (Dade Behring Inc., Newark, DE, USA) and counted in
different fields at a magnification of  100 using a haemocytometer by phase-contrast microscopy. The results are presented as
the average number of invasive cells per representative field.
Estimation of mitochondrial membrane potential (MMP),
caspase activation and DNA fragmentation. PC3M-LN4-Con
and PC3M-LN4-siMIC-1 cells were untreated (control) or treated
with 10 nM docetaxel for 4 days. The adherent and floating cells
were collected, rinsed twice with PBS and centrifuged. For the
MMP estimation, the pellets corresponding to B1  106 PC cells
were resuspended in 1 ml PBS containing the cationic, lipophilic
and fluorescent dye, 40 nM DiOC6(3), which specifically accumulates within the mitochondrial compartment in a MMP-dependent
manner. After incubation at 37 1C for 20 min, the accumulation of
DiOC6(3) within the mitochondria of PC cells was measured by
FACS analyses. Moreover, the amounts of cytochrome c present in
the cytosolic extracts and cleaved caspase-9 or caspase-3 fragment
and cleaved PARP fragment in each sample were estimated by
western blot analyses as described above.
In addition, the qualitative analysis of DNA fragmentation
associated with the apoptotic death of PC3M-LN4-Con and
PC3M-LN4-siMIC-1 cells induced by docetaxel was performed
by the electrophoretic method (Mimeault et al, 2006). Briefly, PC
cells were grown for 4 days without docetaxel (control) or treated
with 10 nM docetaxel. The adherent and floating PC cells were
collected by centrifugation, and DNA from each sample
was extracted using Gentra’s Puregene DNA Isolation Kit
(Qiagen, Valencia, CA, USA) protocol and analysed on a 0.8%
agarose gel electrophoresis. The gel was visualised on UV light after
1081
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Isolation and characterisation of the phenotypic and functional
features of SP and non-SP PC3M-LN4 cell fractions. The
PC3M-LN4 cells (1  106 cells per ml) were stained with 2 mg ml ÿ 1
fluorescent Hoechst dye at 37 1C for 2 h in the absence or presence
of 50 mM verapamil as previously described (Mimeault and Batra,
2009; Mimeault et al, 2010a,b, 2012). The analyses and sorting of
the viable side population (SP) and non-SP cell fractions were done
using a FACS Aria flow cytometer with a DIVA software (Becton
Dickinson Biosciences, San Jose, CA, USA). The monolayer
clonogenic and prostasphere-forming assays were then performed
to estimate the self-renewal capacity of SP vs non-SP PC3M-LN4
cell fractions (Mimeault et al, 2012). Briefly, for each clonogenic
assay, 500 viable SP or non-SP PC3M-LN4 cells were suspended in
serum-free medium supplemented with 1% L-glutamine, antibiotics
and EGF (10 ng ml ÿ 1) onto a 120-mm dish. All samples were
plated in triplicate. After 14 days, the cultures were fixed and
directly stained with a crystal violet solution and colonies were
counted. For prostasphere-forming assay, 500 viable SP or non-SP
PC3M-LN4 cells were suspended in serum-free medium onto a sixwell ultra-low attachment plate (Corning, Invitrogen, Inc., Denver,
CO, USA). All samples were plated in triplicate. After 7 days of
incubation, the number of SP PC3M-LN4 cell-derived prostaspheres was counted and representative pictures of prostaspheres
were photographed by using Accu-scope phase-contrast microscope at a magnification of  200. In addition, PC3M-LN4-Con
and PC3M-LN4-siMIC-1 cells (1  106 cells per ml) were stained
with fluorescent Hoechst dye at 37 1C for 2 h in the absence or
presence of 10 nM docetaxel. The viability of SP and non-SP cells
was analysed by FACS as previously described (Mimeault and
Batra, 2009; Mimeault et al, 2010a, b, 2012).
Statistical analyses. Statistical analyses were performed using the
Student’s t-test to compare the results, with P-values o0.05
indicating statistically significant differences. More specifically,
immunohistochemical data were analysed using MedCalc for
Windows version 9.6.4.0. software (MedCalc Software, Mariakerke,
Belgium). The composite scores of MIC-1 expression were
considered as continuous variables and compared using Student’s
two-tailed t-test assuming unequal variance for independent samples.
RESULTS

Immunohistochemical analyses of MIC-1 expression level in
malignant prostate tissues vs nonmalignant adjacent prostate
tissues. The results from immunohistochemical analyses
have revealed that MIC-1 was overexpressed in 84% of
prostatic adenocarcinomas analysed as compared with normal
prostatic tissues of biopsy (mean of composite scores: 3.9±0.4 vs
0.4±0.3; Pp0.0001), respectively (Figures 1A and B and Table 1).
Moreover, the expression level of MIC-1 was also enhanced in 72%
of prostatic adenocarcinomas analysed relative to their corresponding adjacent benign tissues from 32 PC patients (Gleason
scores ¼ 7–9; mean of composite scores: 3.9±0.4 vs 1.5±0.3;
Pp0.0001), respectively (Figures 1A and B and Table 1). Moreover, the MIC-1 expression in adjacent nonmalignant prostatic
tissue specimens was significantly enhanced in 59% (1.5±0.3)
cases as compared with normal prostatic tissues (0.4±0.3;
Po0.005; Figure 1B and Table 1). More particularly, MIC-1
was weakly expressed in basal and luminal epithelial cells in
normal and adjacent benign prostatic tissues, whereas a higher
expression of MIC-1 was detected in the cytoplasm as well as at or
near the cell surface in luminal and intermediate tumour cells in
malignant prostatic tissues (Figure 1A). Furthermore, the staining
intensity of the secreted MIC-1 protein detected in the stromal
1082
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Figure 1. Immunohistochemical analyses of expression levels of
the MIC-1 protein in nonmalignant and malignant prostatic tissues.
(A) Representative pictures of immunohistochemical analyses of the
expression level of MIC-1 in normal prostatic tissues from biopsies and
adjacent benign and prostatic adenocarcinoma tissues from same PC
patients are shown at original magnifications of  100 and  400.
(B) Comparison of the composite scores of expression levels of MIC-1
in nonmalignant and malignant tissues from PC patients. Box plots
showing the expression levels of MIC-1 in normal prostatic tissues from
biopsies and prostatic adenocarcinoma specimens and their adjacent
benign prostatic tissues. *Po0.005 and 0.0001 indicates a significant
increase between the means of composite scores obtained for adjacent
benign prostatic tissues and prostatic adenocarcinoma tissues relative
to mean of composite scores obtained for normal prostatic tissue
specimens. **Po0.0001 indicates a significant increase between the
mean of composite scores obtained for prostatic adenocarcinoma
tissues compared with mean of composite scores obtained for adjacent
benign prostatic tissue specimens.

compartment was substantially enhanced in PC tissue specimens as
compared with normal and adjacent benign prostatic tissues
(Figure 1A).
www.bjcancer.com | DOI:10.1038/bjc.2012.484
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Table 1. Immunohistochemical analyses of MIC-1 expression in nonmalignant and malignant prostatic tissue specimens

Positive staining
for MIC-1

Mean of composite
scoresa

P-valueb

59%

1.5 ± 0.3 vs 0.4 ± 0.3

Pp0.005

Higher in PC vs normal prostatic tissues

84%

3.9 ± 0.4 vs 0.4 ± 0.3

Pp0.0001

Higher in PC vs adjacent benign
prostatic tissues

72%

3.9 ± 0.4 vs 1.5 ± 0.3

Pp0.0001

Pathological diagnosis
Adjacent nonmalignant prostatic tissue

Number
of cases

Gleason
score

Tumour
stage

32

7–9

2–3

Higher in adjacent benign vs normal
prostatic tissues
Prostatic adenocarcinoma tissue

32

7–9

2–3

Abbreviations: MIC-1 ¼ macrophage inhibitory cytokine-1; PC ¼ prostate cancer.
a
Mean of composite scores±s.e.
b
P-value indicates a significant difference between means of composite scores.

Investigation of the MIC-1 implication for the malignant
behaviour and chemoresistant phenotype of PC3 cells. The
results have indicated that the stimulation of parental PC3 cells
expressing a low level of endogenous MIC-1 protein by 1 ng ml ÿ 1
rhMIC-1, which is included in the range of the physiological serum
concentrations of MIC-1 (E0.7 ng ml ÿ 1) (Brown et al, 2006), does
not influence their proliferation but significantly increased
(Po0.0001) their invasive ability compared with untreated PC3
cells (Figures 2A and 3A). Interestingly, the treatment of starved
PC3 cells with 1 ng ml ÿ 1 rhMIC-1 was also accompanied by a
decreased expression of E-cadherin, which was mainly localised in
the cytoplasm, concomitant with enhanced expression levels of
N-cadherin and vimentin, typical characteristics linked to the
induction of the EMT process (Figures 3B and C). The stimulation
of starved PC3 cells with rhMIC-1 was also associated with a more
intense F-actin staining and cytoskeleton reorganisation, resulting
in the formation of more cytoplasmic projections, including
microspikes, fillopodia- and lamellipodia-like protrusions as
compared with untreated PC3 cells (Figure 3B). Moreover, the
promoting effects induced by exogenous rhMIC-1 on the
invasiveness and acquisition of a EMT phenotype by PC3 cells
was significantly inhibited (Po0.0001) by a selective and potent
inhibitor of type I ALK including ALK4, ALK5 and ALK7 of the
TGF-b superfamily designated as SB431542 (Figures 3A–C). We
have also observed that rhMIC-1-stimulated PC3 cells were less
sensitive to the antiproliferative and anti-invasive effects induced
by docetaxel as compared with untreated PC3 cells (Figures 2A
and 3A). The values of the half-maximal inhibitory concentration
(IC50) obtained for antiproliferative effect induced by docetaxel on
rhMIC-1-stimulated PC3 (7.6±0.6 nM) was significantly higher
than the value for untreated PC3 (4.0±0.3 nM; Po0.01).
Estimation of antiproliferative and anti-invasive effects induced
by docetaxel on PC cells expressing a low or a high level of the
MIC-1 protein. The results from MTT tests and in vitro invasion
assays have indicated that PC3-MIC-1 cells engineered for
overexpressing MIC-1 were less sensitive to the antiproliferative
and anti-invasive effects induced by docetaxel as compared with
PC3-Vect cells expressing a low level of MIC-1 (Figures 2B, C and
3D). The IC50 value obtained for antiproliferative effect induced by
docetaxel on PC3-MIC-1 (6.7±0.6 nM) was significantly higher
than the value for PC3-Vect (3.4±0.2 nM; Po0.0001). In contrast,
the MIC-1 downregulation in LNCaP-LN3-siMIC-1 and PC3MLN4-siMIC-1 cells was accompanied by an enhanced sensitivity of
PC cells to the growth inhibitory effects induced by docetaxel
relative to LNCaP-LN3-Con and PC3M-LN4-Con cells expressing
a high level of MIC-1, respectively (Figures 2B, D and E).
Specifically, the IC50 value obtained for the antiproliferative effect
induced by docetaxel on LNCaP-LN3-siMIC-1 (5.2±0.8 nM) or
www.bjcancer.com | DOI:10.1038/bjc.2012.484

PC3M-LN4-siMIC-1 cells (4.0±0.6 nM) was significantly lower
than the value for LNCaP-LN3-Con (8.5±1.5 nM; Po0.0001) or
PC3M-LN4-Con cells (6.0±0.8 nM; Po0.01), respectively. In
addition, the data from FACS analyses have also revealed that
the 2-day docetaxel treatment of MIC-1-silenced PC3M-LN4siMIC-1 cells resulted in a higher percentage of PC cells in the G2/
M phase in conjunction with a reduction in the number of cells in
the S phase relative to PC3M-LN4-Con cells (Figure 2F and
Supplementary Table S1). Moreover, the data from in vitro
invasion assays have indicated that LNCaP-LN3-siMIC-1 and
PC3M-LN4-siMIC-1 cells displayed a weaker invasive ability and
were more sensitive to the anti-invasive effect induced by docetaxel
than LNCaP-LN3-Con and PC3M-LN4-Con cells (Figure 3E and
F; Po0.0001), respectively.
Determination of the apoptotic effect induced by docetaxel on
PC cells expressing a low or high level of MIC-1 protein. The
apoptotic effect induced by docetaxel on PC cells was estimated by
FACS analyses and the apoptotic cell number in the sub-G1 phase
was quantified. As shown in Figure 4, the increasing concentrations of docetaxel induced a higher rate of apoptotic death on PC3Vec expressing a low level of MIC-1 than on PC3-MIC-1 cells
overexpressing MIC-1. More specifically, 10 nM docetaxel caused a
higher proportion of apoptotic death of PC3-Vect (63±1%) as
compared with PC3-MIC-1 (39±3%; Po0.0001; Figure 4B).
Importantly, MIC-1-silenced LNCaP-LN3-siMIC-1 and PC3MLN4-siMIC-1 cells were also more responsive to the apoptotic
effect induced by docetaxel than LNCaP-LN3-Con and PC3MLN4-Con cells expressing high level of endogenous MIC-1,
respectively (Figure 4). More specifically, 10 nM docetaxel induced
a higher rate of apoptosis in LNCaP-LN3-siMIC-1 (53±5%) and
PC3M-LN4-siMIC-1 cells (52±3%) as compared with LNCaPLN3-Con (38±1%, Po0.0001) and PC3M-LN4-Con cells
(31±1%, Po0.0001), respectively (Figure 4B).
Establishment of the role of mitochondrial and caspase pathways in the apoptotic effect induced by docetaxel on PC3M-LN4
cells expressing a low or high level of MIC-1 protein. An
estimation of the effects of docetaxel treatment on the MMP of
PC3M-LN4-Con cells and PC3M-LN4-siMIC-1 cells was performed by FACS analyses. Moreover, the continuous treatment of
the PC cells for 4 days with 2–10 nM docetaxel was accompanied by
a decrease of MMP, as indicated by the shoulder of the peak and
enhanced percentages of depolarised cells as compared with
stained PC cells that were untreated (control) (Figures 5A and B).
The docetaxel treatment of MIC-1-silenced PC3M-LN4-siMIC-1
cells was, however, accompanied by a higher mitochondrial
membrane depolarising effect and percentage of depolarised cells
as compared with PC3M-LN4-Con cells overexpressing MIC-1
(Figures 5A and B). More specifically, the data of the percentage of
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Figure 2. Effect of the MIC-1 protein on the antiproliferative effect induced by docetaxel on metastatic and AI PC cell lines. The PC cells were
untreated (control) or treated with indicated docetaxel (Doc) concentrations for 2 days and the cell proliferation was evaluated by MTT assays and
FACS analyses. (A) Data obtained by MTT assay for parental PC3 cells expressing a low level of MIC-1 untreated or treated with exogenous rhMIC-1
protein. (B) Immunoblot analyses of the expression levels of MIC-1 protein in culture supernatant and lysates from tested PC cell lines. Data
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with indicated docetaxel concentrations for 2 days.

depolarised cells induced by 10 nM docetaxel on PC3M-LN4siMIC-1 cells (58±6%) were significantly more elevated as
compared with the values obtained for PC3M-LN4-Con cells
(34±2%; Po0.0001; Figure 5B).
Western blot analyses have also indicated that MIC-1-silenced
PC3M-LN4-siMIC-1 cells treated with 10 nM docetaxel showed a
greater amount of cytosolic cytochrome, cleaved fragments of
caspase-9 and caspase-3 and PARP, and DNA laddering than
PC3M-LN4-Con cells (Figures 5C and D). Moreover, the results
from FACS analyses have revealed that the broad-spectrum caspase
1084

inhibitor Z-VAD-FMK at 50 mM markedly abrogated the percentage of apoptotic death induced by docetaxel on all tested PC cells
(Figure 4B).
Characterisation of SP and non-SP PC3M-LN4 cells and the
estimation of cytotoxic effects induced by the downregulation of
MIC-1 and docetaxel treatment. The results from FACS analyses
have indicated the presence of a small SP cell subpopulation
representing B0.87% of the total mass of PC3M-LN4 cells
(Figure 6A). The SP cell fraction was significantly reduced in the
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Figure 3. Effect of the MIC-1 protein on the invasive ability of PC cells and the anti-invasive effect induced by docetaxel treatment on PC cell
lines expressing low and high levels of the MIC-1 protein. The PC cells were untreated (control) or treated with the indicated agents, plated on
matrigel-coated membrane for invasion assays and incubated for 24 h. Data of the invasive ability obtained for (A) parental PC3 cells after a
treatment with 1 ng ml ÿ 1 rhMIC-1 protein in the absence or presence of 10 mM SB431542 or 10 nM docetaxel. The results from comparative
analyses by (B) confocal microscopy and (C) western blot of the effect induced by a treatment of starved PC3 cells with 1 ng ml ÿ 1 rhMIC-1 in the
absence or presence of 10 mM SB431542 on expression levels and intracellular localisation of different gene products associated with the EMT
process. Data of the invasive ability obtained for (D) PC3-Vect cells expressing a low level of MIC-1 vs PC3-MIC-1 cells engineered for
overexpressing MIC-1 protein, and (E) scrambled LNCaP-LN3-Con and (F) PC3M-LN4-Con cells overexpressing high levels of endogenous MIC-1
vs MIC-1-silenced LNCaP-LN3-siMIC-1 and PC3M-LN4-siMIC-1 cells, respectively.

presence of the ABC transporter inhibitor, 50 mM verapamil,
indicating that the SP phenotype may be associated with a high
expression of ABC multidrug efflux pumps (Figure 6A). Moreover,
the FACS analyses after staining of PC3M-LN4 cells with
phycoerythrin-labelled CD133 antibody have also indicated the
presence of a small PC3M-LN4 cell population expressing a high
level of a CD133 stem cell-like marker corresponding to B0.79%
of the total PC3M-LN4 cell mass (Figure 6B). We have also
observed that SP PC3M-LN4 cells displayed a greater clone
formation efficacy and were able to generate many dense
prostaspheres with a large size (72±3 prostaspheres for 500
plated SP cells) in serum free-medium under ultra-low attachment
plate as compared with non-SP cells (Figures 6C and D).
Moreover, SP PC3M-LN4 cells also expressed higher levels of
stem cell-like markers, including CD133, CD44 and ABCG2
www.bjcancer.com | DOI:10.1038/bjc.2012.484

multidrug transporter, and EMT-associated molecules, such
as N-cadherin and vimentin, relative to the non-SP cell
fraction (Figures 6E–G). Interestingly, SP and non-SP PC3MLN4 cell fractions also expressed significant levels of MIC-1,
EGFR and its phosphorylated Tyr1173-pEGFR form and F-actin
(Figures 6E and G).
Importantly, the results from FACS analyses have also revealed
that the treatment of PC3M-LN4-Con cells with 10 nM docetaxel
for 4 days was accompanied by a significant increase in the
percentage of viable SP cells, whereas the number of cells in the
bulk PC cell mass was reduced as compared with the nontreated
cells (Figure 6H). The MIC-1 silencing in PC3M-LN4-siMIC-1
cells was, however, accompanied by a significant decrease of
viable SP and the bulk PC cell mass, including non-SP cells
(Figure 6H). Of therapeutic interest, the docetaxel treatment of
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Figure 4. Fluorescence-activated cell sorting (FACS) analyses of the
apoptotic effect induced by docetaxel on PC cell lines expressing low
and high levels of the MIC-1 protein. Plots showing the percentages of
apoptotic cell death induced after 4 days of treatment of PC cells with
indicated docetaxel concentrations in the absence or presence of
broad caspase inhibitor, Z-VAD-FMK, at 50 mM, which was estimated
by the number of apoptotic cells detected in the sub-G1 phase by
FACS analyses. Quantitative data obtained for (A) PC3-Vect cells
expressing a low level of MIC-1 vs PC3-MIC-1 cells engineered for
overexpressing MIC-1 protein, and (B and C) scrambled LNCaP-LN3Con and PC3M-LN4-Con cells overexpressing high levels of
endogenous MIC-1 vs MIC-1-silenced LNCaP-LN3-siMIC-1 and
PC3M-LN4-siMIC-1 cells, respectively.

PC3M-LN4-siMIC-1 cells was also associated with a greater
decrease in the percentage of viable SP cells as well as the number
of cells in the bulk PC cell mass, including non-SP cells, relative to
PC3M-LN4-Con cells treated with 10 nM docetaxel (Figure 6H).

DISCUSSION

The results of the present investigation have provided new lines of
experimental evidence for a direct association of the enhanced
expression of secreted MIC-1 protein with the acquisition of
aggressive and chemoresistant phenotypes by PC cells during
disease progression. More specifically, the data from immunohistochemical analyses have revealed that the expression of the MIC-1
protein was enhanced in PC cells in 83% and 72% of primary
prostatic adenocarcinomas from PC patients (Gleason scores ¼ 7–9)
as compared with normal prostatic tissues of biopsy and adjacent
benign prostatic tissues from the same patients, respectively
(Figures 1A and B and Table 1). In addition, the data from
western blot have also indicated that the highly metastatic and AI
LNCaP-LN3 cells expressing a functional androgen receptor (AR)
and AR- PC3M-LN4 cell line, which has previously been observed
to display a higher propensity to metastasise to bones than the PC3
cell line, expressed a high level of MIC-1 (Figure 2B) (Pettaway
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et al, 1996). Together, these data support numerous prior studies
indicating that a progressive increase of the MIC-1 level occurs in
PC cells during prostate carcinogenesis and PC progression of
androgen-sensitive to androgen-independent and metastatic disease states (Karan et al, 2002, 2003; Nakamura et al, 2003; Welsh
et al, 2003; Cheung et al, 2004; Bauskin et al, 2005; Brown et al,
2006; Chen et al, 2007; Huang et al, 2007; Patrikainen et al, 2007;
Selander et al, 2007; Brown et al, 2009; Wakchoure et al, 2009;
Zhao et al, 2009; Senapati et al, 2010; Mimeault et al, 2012). More
specifically, a significant increase of MIC-1/GDF15 expression, at
both the mRNA and mature protein level, has been detected in
prostatic hyperplasia and prostatic intraepithelial neoplastic (PIN)
lesions formed in the LBT Tag 12T-7s transgenic mouse model, a
modified SV40 early region driven by the prostate-specific rat
probasin promoter, and associated with a stimulation of prostatic
epithelial cell proliferation (Kasper et al, 1998; Noorali et al, 2007).
These data suggest that an enhanced expression of the mature
MIC-1/GDF-15 form may constitute an early transforming event
during prostate carcinogenesis. Moreover, the enhanced expression
of MIC-1 in prostatic adenocarcinoma tissues and/or serum
samples has been positively correlated with the presence of
metastatic PCs and poor prognosis of PC patients as a result of
treatment resistance (Karan et al, 2002; Nakamura et al, 2003;
Welsh et al, 2003; Cheung et al, 2004; Bauskin et al, 2005; Brown
et al, 2006; Huang et al, 2007; Patrikainen et al, 2007; Selander
et al, 2007; Brown et al, 2009; Zhao et al, 2009; Mimeault et al,
2010a). In addition, the results of our recent work have also
revealed that the expression levels of MIC-1 protein were increased
in CD133 þ PC cell subpopulation and the bulk mass of CD133PC cells in prostatic adenocarcinoma tissues as well as in PC cells
detected in bone metastasis tissue specimens from PC patients
relative to normal prostate tissues (Mimeault et al, 2012).
Altogether, these observations suggest that an enhanced expression
of MIC-1 frequently occurs in PC cells during PC progression and
in bone metastases and may contribute to disease relapse. This
supports great interest to further investigate the possibility to use
MIC-1 as prognostic indicator, alone or in combination with other
current clinical biomarkers, to predict the risk of PC progression to
AI, metastatic and recurrent disease states.
In addition, the results have also revealed that an increase of the
expression level of secreted MIC-1 cytokine may be associated with
the acquisition of a more malignant behaviour by metastatic and
AI PC cells. Particularly, we have observed that the exogenous
rhMIC-1 treatment or ectotopic overexpression of MIC-1 in PC3
cells was accompanied by a significant increase of their invasive
ability, whereas the MIC-1 downregulation in highly metastatic
LNCaP-LN3 and PC3M-LN4 cells markedly decreased their
invasiveness (Figures 3A, D, E and F). Our results have also indicated that the treatment of PC3 cells with rhMIC-1 upregulated the
expression of the EMT programme-associated molecules, including
mesenchymal markers, N-cadherin and vimentin, concomitant
with a decreased expression of epithelial marker E-cadherin.
Moreover, the treatment of PC3 cells with rhMIC-1 also induced a
F-actin reorganisation, at least in part, via the activation of type I
ALK receptors of TGF-b superfamily (Figures 3B and C). These
data support previous studies indicating that the secreted MIC-1
protein may mediate its effects through TGF-b superfamily
receptors, and TGF-b family members can cooperate with other
growth factors including EGF to induce a partial or full EMT
programme in cancer cells, including PC3 cells (Tan et al, 2000; Xu
et al, 2006; Johnen et al, 2007; Soto-Cerrato et al, 2007; Kong et al,
2008; Odero-Marah et al, 2008; Ago et al, 2010; Lenferink et al,
2010; Mimeault et al, 2010a, b; Lim et al, 2011). These
observations are also in agreement with prior investigations that
have shown that the MIC-1 overexpression in metastatic and
androgen-sensitive AR þ LNCaP-C33 and AI AR þ LNCaP-LN3
and AR- PC3 cells enhanced their migratory and invasive abilities
www.bjcancer.com | DOI:10.1038/bjc.2012.484
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Figure 5. Stimulatory effect induced by docetaxel on mitochondrial membrane depolarisation, cytosolic cytochrome c releasing, caspase
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10 nM docetaxel for 4 days.

in vitro (Chen et al, 2007; Senapati et al, 2010). Importantly, it has
also been reported that the intraprostatic orthotopically implanted
PC3 cells engineered for overexpressing MIC-1 in nude mice
developed metastases in regional and distant organs, whereas no
metastasis was seen in the animal group implanted with emptyvector-transfected PC3 cells (Senapati et al, 2010). Hence, these
results suggest that MIC-1 can provide critical functions for
invasion and metastatic spread to distant tissues including lymph
nodes and bones of PC cells, at least in part, by inducing the EMT
programme via TGF-b superfamily receptors.
Although the development of early detection tests had led to an
improvement in prognosis for patients with localised PCs treated
with prostatectomy, AI lesions may eventually develop and
progress despite low levels of circulating androgens (Tannock
et al, 2004; Mimeault and Batra, 2006; Freedland, 2010). Patients
with locally advanced or metastatic CRPCs, resistant to antihormonal therapy, radiotherapy and first-line systemic docetaxelbased chemotherapies, are usually dead after 12 to 19 months
(Petrylak et al, 2004; Tannock et al, 2004; Mimeault and Batra,
2006; Freedland, 2010; Siegel et al, 2012). In this regard, we have
shown that a downregulation of the MIC-1 expression in highly
metastatic LNCaP-LN3-siMIC-1 and PC3M-LN4-siMIC-1 cells
was accompanied by an increase of their sensitivity to antiproliferative and anti-invasive effects induced by the current
chemotherapeutic drug, docetaxel (Figures 2 and 3 and
Supplementary Table S1). The MIC-1-silenced LNCaP-LN3siMIC-1 and PC3M-LN4-siMIC-1 cells were also more sensitive
to the apoptotic effect induced by docetaxel through a mitochondria- and caspase activation-dependent pathway (Figures 4 and 5).
These data support prior studies that have indicated that MIC-1
can contribute to aggressive behaviour and docetaxel resistance of
PC cells (Huang et al, 2007; Zhao et al, 2009). For instance, it has
been reported that PC3-Rx cells made resistant to docetaxel
exhibited a greater expression level of MIC-1 relative to the
parental PC3 cell line (Zhao et al, 2009). Also, the overexpression
of MIC-1 in metastatic and AI PC3 and DU145 cells or a treatment
www.bjcancer.com | DOI:10.1038/bjc.2012.484

with exogenous rhMIC-1 enhanced their resistance to cytotoxic
effects induced by docetaxel or mitoxantrone in vitro (Huang et al,
2007; Zhao et al, 2009). Moreover, it has also been observed that
the MIC-1 concentrations detected in serum/plasma were more
elevated after docetaxel treatment and associated with the PC
progression and a shorter survival of PC patients (Huang et al,
2007; Zhao et al, 2009). In addition, higher serum levels of MIC-1
were also detected in PC patients with bone metastases as
compared with patients without bone metastases (Selander et al,
2007). The patients who developed bone relapse had significantly
higher serum levels of MIC-1 relative to patients who did not
(Selander et al, 2007). It has also been noticed that PC cells
expressing MIC-1 can induce mixed osteoblastic/osteolytic lesions,
suggesting a critical role for secreted MIC-1 in the development of
these pathological complications of bone metastases (Wakchoure
et al, 2009).
Importantly, numerous recent studies have revealed that distinct
subsets of highly tumourigenic PC stem/progenitor cells expressing
stem cell-like markers such as CD133, CD44high, ALDHhigh, Oct-3/4,
Nanog, Sox-2 and/or ABCG2 and EMT-associated molecules but
undetectable or low level of AR and prostate-specific antigen (PSA)
can be more resistant than the bulk mass of PC cells to current
androgen deprivation and chemotherapy (Patrawala et al, 2007;
Birnie et al, 2008; Duhagon et al, 2010; Kong et al, 2010; Liu et al,
2010; Mimeault and Batra, 2010b; Jeter et al, 2011; Mimeault and
Batra, 2011a; Rajasekhar et al, 2011; Dubrovska et al, 2012;
Germann et al, 2012; Lee et al, 2013; Mimeault et al, 2012; Sun
et al, 2012). Consequently, the persistence and enrichment of PC
stem/progenitor cells after treatment initiation may lead to the
tumour re-growth, metastases and disease relapse (Patrawala et al,
2007; Klarmann et al, 2009; Liu et al, 2010; Mimeault et al, 2010a;
Jeter et al, 2011; Mimeault and Batra, 2011a; Dubrovska et al, 2012;
Germann et al, 2012; Lee et al, 2013; Mimeault et al, 2012; Sun
et al, 2012). Of therapeutic interest, the results of the present study
have revealed that the downregulation of MIC-1 was effective in
enhancing the sensitivity of the SP PC3M-LN4 cell subpopulation
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Figure 6. Characterisation of phenotypic and functional features of SP and non-SP PC3M-LN4 cell fractions and the implication of MIC-1 in their
sensibility to the cytotoxic effect induced by docetaxel. (A) Hoechst dye efflux profiles obtained for parental PC3M-LN4 cells stained with
fluorescent Hoechst dye in the absence or presence of 50 mM verapamil showing SP cells (green) and the non-SP fraction (blue) and (B) FACS
profiles obtained after staining of PC3M-LN4 cells with phycoerythrin-labelled anti-CD133 antibody. (C) Clone formation efficacy of SP and non-SP
PC3M-LN4 fractions and (D) representative pictures of dense prostaspheres formed by SP PC3M-LN4 cells as compared with small aggregates
formed by non-SP PC3M-LN4 cells. (E–G) Comparative western blot and immunoconfocal analyses of expression levels of different markers in SP
and non-SP PC3M-LN4 cell fractions. (H) Hoechst dye efflux profiles obtained for PC3M-LN4-Con cells overexpressing endogenous MIC-1 and
MIC-1-silenced PC3M-LN4-siMIC-1 cells untreated or treated with 10 nM docetaxel for 4 days.

endowed with a high self-renewal and expressing high levels of
stem cell-like markers and EMT-associated molecules as well as the
bulk mass of PC cells including non-SP cells to cytotoxic effects of
docetaxel (Figure 6). Hence, these observations support great
interest to target the MIC-1 signalling cascade to eradicate AI,
metastatic and chemoresistant PC stem/progenitor cells endowed
with stem cell-like and EMT properties to counteract disease
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progression to metastatic CRPCs. In this regard, the data of prior
microarray analyses have also indicated that the prostaspheres
formed by LNCaP cells in serum-free medium expressed a higher
level of MIC-1/GDF-15 as compared with LNCaP cells grown in
medium containing 10% serum (Duhagon et al, 2010). It has also
been reported that the inhibition of LuCaP35 tumour growth
induced by androgen-deprivation therapy was associated with
www.bjcancer.com | DOI:10.1038/bjc.2012.484
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enhanced expression levels of stem cell-like markers and EMTassociated molecules such as N-cadherin, vimentin and twist and
activated TGF-b signalling pathway in tumours (Sun et al, 2012).
Moreover, LNCaP cells cultured in medium containing charcoalstripped serum (CSS) also exhibited a higher resistance to
docetaxel than LNCaP cells grown in CSS plus a-dihydrotestosterone (Sun et al, 2012). Interestingly, the data from a recent study
have also indicated that PSA-/low/AR-/low PC or PSA-/low/AR þ cells,
which harbour a subpopulation of highly tumourigenic CD44 þ /
a2b1þ /ALDH þ PC cell, detected in LNCaP, LaPC9 or primary PC
cells displayed a higher self-renewal and tumourigenic abilities
than PSA þ PC cells (Qin et al, 2012). In addition, PSA-/low PC cells
were also more resistant to androgen-deprivation therapy and
chemotherapy, including paclitaxel, than the bulk mass of
differentiated PSA þ PC cells in vitro and in vivo (Qin et al, 2012).
Taken together, the results of the present investigation have
revealed that the overexpression of MIC-1 in metastatic
and androgen-sensitive and AI AR þ and AR- PC cells can
contribute to their acquisition of a more aggressive behaviour,
EMT phenotypes and docetaxel resistance. Importantly, the data
have also indicated that the downregulation of MIC-1 in AI PC
cells, including PC stem/progenitor cells, may represent a
promising therapeutic strategy to improve the anticarcinogenic
efficacy of docetaxel, by eradicating the total PC cell mass and
thereby preventing disease progression and relapse, and the death
of PC patients.
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